Inovio Pharmaceuticals (INO) Stock Price, News & Analysis

Company Overview

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells.

Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases. The company has also developed INO-4800, an investigational DNA vaccine candidate for COVID-19. Its technology platform includes CELLECTRA, a proprietary device and electroporation system designed to improve the delivery of DNA medicines.

Founded in 1983 as Genetronics, the company adopted the name Inovio Pharmaceuticals in 2009. Inovio is headquartered in Plymouth Meeting, Pennsylvania, and conducts research and clinical development activities through collaborations and trials in the United States and other international markets. Its products remain primarily investigational and are subject to regulatory review.

Key Stats

• Today's Range: $1.30 to $1.48
• 50-Day Range: $0.60 to $1.89
• 52-Week Range: $0.56 to $2.72
• Volume: 10.79 million shs
• Average Volume: 26.57 million shs
• Market Capitalization: $162.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.33
• Consensus Rating: Moderate Buy

Inovio Pharmaceuticals Stock Analysis - MarketRank™

Inovio Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 395th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Inovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Inovio Pharmaceuticals has a consensus price target of $6.33, representing about 329.4% upside from its current price of $1.48.

Amount of Analyst Coverage

Inovio Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($0.74) to ($0.42) per share.

Price to Book Value per Share Ratio

Inovio Pharmaceuticals has a P/B Ratio of 4.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.41% of the float of Inovio Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 1.82, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Inovio Pharmaceuticals has recently increased by 3.74%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inovio Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Inovio Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.56

News Sentiment

Inovio Pharmaceuticals has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 29 news articles for Inovio Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

40 people have searched for INO on MarketBeat in the last 30 days. This is an increase of 208% compared to the previous 30 days.

MarketBeat Follows

10 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of Inovio Pharmaceuticals is held by insiders.

Percentage Held by Institutions

26.79% of the stock of Inovio Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 11/10/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INO
• CIK: 1055726
• Web: www.inovio.com
• Phone: (858) 410-3134
• Fax: 267-440-4242
• Employees: 112
• Year Founded: 1979

Price Target and Rating

• Average Price Target for Inovio Pharmaceuticals: $6.33
• High Price Target: $8.00
• Low Price Target: $5.00
• Potential Upside/Downside: +329.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$84.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -383.92%
• Return on Assets: -76.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.00
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $60 thousand
• Price / Sales: 2,708.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.36 per share
• Price / Book: 4.10

Miscellaneous

• Outstanding Shares: 110,180,000
• Free Float: 108,309,000
• Market Cap: $162.52 million
• Optionable: Optionable
• Beta: 1.71